16.9 C
New York
Thursday, May 19, 2022

NeuroBo Pharmaceuticals, Inc. (NRBO) Stock Soaring High in Aftermarket Despite any Clear Reason.

NeuroBo Pharmaceuticals, Inc. (NRBO) is a leader in the development of biotherapeutics for the treatment of neurodegenerative and neuropathic diseases. The lead pipeline products include ANA001 in Phase 2/3 trials for treating COVID-19 patients, NB-01 in Phase 2 studies for painful diabetic neuropathy, and NB-02 for Alzheimer’s disease.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


NRBO stock price in the regular trading session of March 18, 2022, with a gain of 2.87% was $0.84. Its price surged phenomenally as of this writing in the aftermarket session by 28.5%.

NRBO: Events and Happenings

On March 15, 2022, NRBO updated on appointing Danamarie Belpulsi to the company’s Scientific Advisory Board with immediate effect. He served as the Medical Director at ICON plc. On January 28, 2022, NRBO stated appointing D. Gordon Strickland as a member of its Board of Directors along with Chair of its Audit Committee, with effect from January 27, 2022. He previously served as Ampex Corporation’s Chairman.

NRBO: Key Financials

On November 15, 2021, NRBO released the unaudited financial statement for Q3 2021 ended September 30, 2021. Some of the important highlights are mentioned below.


No revenue was recorded by the company during the third quarter of 2021 as well as the same period of 2020.


Per-share basic and diluted net loss during Q3 2021 was $3.5 million, or $0.16 against $3.1 million or $0.19 for the corresponding quarter in 2020. Its EPS surpassed the experts’ estimations by $0.02 and the EPS gained momentum YoY.

On October 13, 2021, NRBO updated on the review of the safety data for Phase 2/3 clinical trials of ANA001 by a Data Monitoring Committee. The outcomes suggested the continuity of the studies without any modifications.


NRBO stock down-performed by 37% and 82% in the YTD and previous year period respectively. Its recent gain in the price is the likely consequence of uncertainty as there is no recent official press release or SEC filing by the company. Its stock price shows that the investors are taking interest in the company’s policies.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles